| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
Radioisotope (RI)-labeled peptides have been studied as agents for cancer radiotherapy. However, their clinical application is difficult because of the high accumulation in the kidney, which results in unnecessary radiation exposure. Our previous study revealed that introducing negative charge into RI-labeled peptide could reduce the accumulation of renal radioactivity. In addition, to maintain the residence time of peptide in tumor cells, it is important to introduce negative charge into a suitable position on the molecule. The present study aimed to develop RI-labeled peptides both reducing radioactivity levels in kidney and maintaining the accumulation in tumor by the introduction of negative charge. As a result, I synthesized a new RI-labeled peptide derivative, achieving not only the reduction of renal radioactivity but also augmented tumor radioactivity. An application for radiotherapy using this RI-labeled peptide will be evaluated in tumor-bearing animals in the near future.
|
